The analysis of the factors related to efficacy of asunaprevir and daclatasvir hydrochloride for hepatitis C-related liver disease - antiviral therapy with asunaprevir and daclatasvir hydrochloride

Kanazawa University0 个研究点目标入组 300 人开始时间: 2015年2月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with a history of hypersensitivity to any ingredient contained in asunaprevir and daclatasvir hydrochloride [Contraindications in the package insert] 2)Pregnant women, women suspected of being pregnant, or lactating women [Contraindications in the package insert] 3)Patients who are receiving any of the following drugs [Contraindications for coadministration in the package insert] Rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital, systemic dexamethasone, food products containing St. John's wort, azole antifungal agents, clarithromycin, erythromycin, diltiazem, verapamil hydrochloride, drug products containing cobicistat, HIV protease inhibitor, modafinil, non-nucleoside reverse transcriptase inhibitor, bosentan hydrate, cyclosporine, flecainide, propafenone 4)Patients with moderate (Child-Pugh Class B or C) hepatic impairment or those with decompensated liver disease (poorly controlled ascites or hepatic encephalopathy, T.Bil 3.0 mg/dl or above) [Contraindications in the package insert] 5)Patients who are considered by the investigators as inappropriate to be study patients [established for the sake of patient safety]. Patients who meet any of the following criteria will be ineligible for inclusion in the study 6)Patients who received treatment of liver cancer within the past 6 months 7)Patients who are considered by the investigators/subinvestigators as inappropriate to be subjects.

发起方